|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Golimumab in real-world practice in patients with ulcerative colitis:Twelve-month results显示文摘BACKGROUND The introduction of biologics has revolutionized the management of the chronic inflammatory bowel disease,ulcerative colitis(UC),with many patients experiencing significant improvements not only in their symptoms but in other outcomes relevant to individuals and society as a whole.In Germany,there are no prospective data>3 mo that assess the work productivity,daily activities and quality of life(QoL)of patients with moderate-to-severe UC treated with golimumab.AIM To assess change in work productivity,capacity for daily activities and QoL in UC patients treated with golimumab in Germany.METHODS The validated Work Productivity Activity Impairment(WPAI)Questionnaire was used to analyze the change in work productivity,the capacity for daily activities after three months(primary endpoint)and disease specific and health related QoL(HRQoL)up to 1 year(secondary endpoints).The changes in work productivity and activity impairment were evaluated every three months until month twelve compared to baseline.Disease-specific and health-related QoL were assessed with the inflammatory bowel disease questionnaire and with the short-form 12 health survey questionnaire(SF-12).RESULTS This prospective non-interventional study included 287 patients.The analysis population was comprised of 282 patients who had completed at least two visits.At baseline,61%of patients had moderate UC and 18%had severe UC.Furthermore,75%of patients worked full-time or part-time at baseline.A total of 212 patients who were employed at the start of the study(employed population)were evaluated for the primary endpoint.Golimumab significantly reduced all WPAI sub-scores compared to baseline after three,six,nine and twelve months after the start of treatment(P<0.0001).In addition,disease-specific QoL and HRQoL,as measured by the SF-12 questionnaire,improved significantly with golimumab at all evaluation times(P<0.0001 in each case vs baseline).CONCLUSION Treatment of moderate-to-severe UC with golimumab leads to significant improvements in patient´s work productivity,daily activity and QoL over twelve months. | Niels Teich Harald Grümmer Eric Jorgensen Thomas Liceni Frank Holtkamp-Endemann Tim Fischer Susanne Hohenberger | 2020 | World Journal of Gastroenterology2020，26，21： | 3 |
| 2 | Parameters of a severe disease course in ulcerative colitis显示文摘AIM:To detect high risk patients with a progressive disease course of ulcerative colitis(UC) requiring immunosuppressive therapy(IT).METHODS:A retrospective,multicenter analysis of 262 UC patients from eight German tertiary inflammatory bowel disease centres was performed.Patients were divided into two groups depending on the patients need to initiate immunosuppressive therapy in the disease course.A comparison between the two groups was made with regard to demographics,clinical and laboratory parameters obtained within three months after UC diagnosis and the response to first medical therapy.Using this data,a prognostic model was established to predict the individual patients probability of requiring an immunosuppressive therapy.RESULTS:In 104(39.7%) out of 262 patients,UC therapy required an immunosuppressive treatment.Patients in this group were significantly younger at time of diagnosis(HR = 0.981 ± 0.014 per year,P = 0.009),and required significantly more often a hospitalisation(HR = 2.5 ± 1.0,P < 0.001) and a systemic corticosteroid therapy at disease onset(HR = 2.4 ± 0.8,P < 0.001),respectively.Response to steroid treatment was significantly different between the two groups of patients(HR = 5.2 ± 3.9 to 50.8 ± 35.6 compared to no steroids,P = 0.016 to P < 0.001).Furthermore,in the IT group an extended disease(HR = 3.5 ± 2.4 to 6.1 ± 4.0 compared to proctitis,P = 0.007 to P = 0.001),anemia(HR = 2.2 ± 0.8,P < 0.001),thrombocytosis(HR = 1.9 ± 1.8,P = 0.009),elevated C-reactive protein(CRP)(HR = 2.1 ± 0.9,P < 0.001),and extraintestinal manifestations in the course of disease(HR = 2.6 ± 1.1,P = 0.004) were observed.Six simple clinical items were used to establish a prognostic model to predict the individual risk requiring an IT.This probability ranges from less than 2% up to 100% after 5 years.Using this,the necessity of an immunosuppressive therapy can be predicted in 60% of patients.Our model can determine the need for an immunosuppressive drug therapy or if a 'watch and wait' approach is reasonable already early in the treatment course of UC.CONCLUSION:Using six simple clinical parameters,we can estimate the patients individual risk of developing a progressive disease course. | Andreas Stallmach Luisa Nickel Thomas Lehmann Bernd Bokemeyer Martin Bürger Dietrich Hüppe Wolfgang Kruis Susanna Nikolaus Jan C Preiss Andreas Sturm Niels Teich Carsten Schmidt | 2014 | World Journal of Gastroenterology2014，20，35： | 2 |
| 3 | A multi-attribute e-auction mechanism for procurement: Theoretical foundations显示文摘 | Jeffrey E. Teich Hannele Wallenius Jyrki Wallenius Alexander Zaitsev | 2005 | European Journal of Operational Research2005，，1： | 2 |
| 4 | Synthesis and biological evaluation of new derivatives of emodin 显示文摘 | Lars Teich Katja Scarlett Daub Vera Krugel | 2004 | Bioorg Med Chem2004，12，22： | 1 |
| 5 | Wound management with vacuum-assisted closure:experience in 51 pediatric patients显示文摘 | CANIANO D A RUTH B TEICH S | 2005 | J Pediatr Surg2005，40，1： | 1 |
| 6 | Optimizing the Selection of Partners in Production Networks显示文摘 | FISCHER M JAHN H TEICH T | 2004 | Robotics and Computer-Integrated Manufacturing2004，20，3： | 1 |
| 7 | Analysis of the cost-effectiveness of thrombolysis with alteplase in stroke 显示文摘 | Ara6jo DV Teich V Passos RB | 2010 | Arq Bras Cardiol2010，95，1： | 1 |
| 8 | Bidding strategies for real-life small loan auctions显示文摘 | Puro Lj Teich J E Wallenius H | 2011 | Decision Support Systems2011，51，1： | 1 |
| 9 | Hereditary chronic pancreatitis显示文摘 | Teich N Mossner J | 2008 | Best Pract Res Clin Gastroenterol2008，221，： | 1 |
| 10 | Designing electronic auctions: an internet-based hybrid procedure combining aspects of negotiations and auctions显示文摘 | Teich J E Wallenius H Wallenius J | 2001 | Electronic Commerce Research2001，1，3： | 1 |
| 11 | A roadmap for national action on clinical decision support 显示文摘 | OSHEROFF J A TEICH J M MIDDLETON B | 2007 | Journal of the American Medical Informatics Association2007，14，2： | 1 |
| 12 | Decision support for multi-unit combinatorial bundle auctions 显示文摘 | Leskela R L Teich J Wallenius H | 2007 | Decision Support Systems2007，43，2： | 1 |
| 13 | Binomial States of the Quantized Radiation Field显示文摘 | STOLER D SALEH B E A TEICH M C | 1985 | Opt Acta1985，32，： | 1 |
| 14 | Optimizing the selection of partners in production networks显示文摘 | MARCO Fischer HENDRIK Jahn TOBIAS Teich | 2004 | Robotics and computer-Integrated manufacturing2004，20，： | 1 |
| 15 | Initial population construction for convergence improvement of moeas显示文摘 | Haubelt C Gamenik J Teich J | 2005 | In Coello C Aguirre A Zitzler E eds:Evolutionary Multicritenion Optimization EMO''20052005，3410，： | 1 |
| 16 | System-oriented and Text-oriented Comparative Linguistic Research: Cross-linguistic Variation in Translation 显示文摘 | Teich E | 1999 | Languages in Contrast1999，，2： | 1 |
| 17 | Wound management with vacuum- assisted closure:experience in 51 pediatric patients显示文摘 | Caniano DA Ruth B Teich S | 2005 | J Pediatr Surg2005，40，1： | 1 |
| 18 | A multi-attribute e-auction mechanism for procurement: Theoretical foundations显示文摘 | Teich J E Wallenius H Wallenius J | 2006 | European Journal of Operational Research2006，175，1： | 1 |
| 19 | Optimizing the Selec- tion of Partners in Production Networks显示文摘 | Fischer M Jahn H Teich T | 2004 | Robotics and Computerintegrated Manufacturing2004，20，6： | 1 |
| 20 | Optimizing the selection of partners in production networks显示文摘 | Fischer M Jahn H Teich T | 2004 | Robotics and Computer-Integrated Manufacturing2004，20，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员